Aerovate Therapeutics, Inc. AVTE NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

49/100

2/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Aerovate Therapeutics, Inc. (AVTE) .

Criteria proven by this page:

VALUE (100/100, Pass) — analyst target implies upside (+385.1%).
Analyst consensus target $13.00 (+385.1% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 48/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

49/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

Proven by this page

FUTURE

52/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

28/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — AVTE

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-3,193.30

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

Analyst Target$13.00 (+385.1%)

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2019	$-0.14	$0.00	$-3.33M	-
2020	$-40.17	$0.00	$-9.61M	-
2021	$-1.87	$0.00	$-22.96M	-
2022	$-2.10	$0.00	$-51.51M	-
2023	$-2.87	$0.00	$-75.52M	-
2024	$-2.44	$0.00	$-69.63M	-
2025	$-3,193.30	$0.00	$-127.41M	-